Document Detail


Low dose recombinant interferon alfa treatment for classic Kaposi's sarcoma.
MedLine Citation:
PMID:  8215494     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: High doses of interferon alfa are used to treat Kaposi's sarcoma in patients with immunodeficiency, whereas low doses are generally ineffective. Following low-dose recombinant interferon alfa treatment for lymphoma, two patients showed a regression of their hematologic malignancy-associated Kaposi's sarcoma. This observation prompted us also to try low-dose interferon alfa treatment in uncomplicated classic Kaposi's sarcoma, and two additional patients were thus treated on an outpatient basis. OBSERVATIONS: Initial response was noted after 3 to 13 weeks of treatment. Remission was achieved after 4 to 6 months of low-dose interferon alfa treatment and its duration was 8 to 14 months. Recurrences were treated again and additional remissions were obtained after only 5 to 8 weeks of treatment. CONCLUSION: Low-dose interferon alfa treatment may represent an effective therapeutic modality for the treatment of patients with both lymphoma-associated and uncomplicated classic Kaposi's sarcoma.
Authors:
E Tur; S Brenner; R Michalevicz
Related Documents :
1851324 - Low frequency maintenance ganciclovir for cytomegalovirus retinitis.
23480824 - Out-of-hospital cardiac arrest: 10 years of progress in research and treatment.
8922804 - Cytarabine therapy for progressive multifocal leukoencephalopathy in patients with aids.
6386264 - Antibiotic-loaded acrylic cement: current concepts.
18768214 - Ca125 decline in ovarian cancer patients treated with intravenous versus intraperitonea...
19367254 - Primary mediastinal large b-cell lymphoma.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Archives of dermatology     Volume:  129     ISSN:  0003-987X     ISO Abbreviation:  Arch Dermatol     Publication Date:  1993 Oct 
Date Detail:
Created Date:  1993-11-02     Completed Date:  1993-11-02     Revised Date:  2008-03-17    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1297-300     Citation Subset:  AIM; IM    
Affiliation:
Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Sackler School of Medicine, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Female
Humans
Interferon Type I, Recombinant / administration & dosage*
Male
Middle Aged
Sarcoma, Kaposi / therapy*
Skin Neoplasms / therapy*
Chemical
Reg. No./Substance:
0/Interferon Type I, Recombinant
Comments/Corrections
Comment In:
Arch Dermatol. 1994 Jun;130(6):799-801   [PMID:  8043141 ]
Arch Dermatol. 1993 Oct;129(10):1320-3   [PMID:  8215499 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nonmelanoma skin cancer mortality in the United States, 1969 through 1988.
Next Document:  Leukemia cutis in congenital leukemia. Analysis and review of the world literature with report of an...